Citations

Citations to this article as recorded by  

• Glucosamine supplementation attenuates progression of metabolic dysfunction-associated steatotic liver disease and related comorbidities
  Tom Ryu, Young Chang, Jeong-Ju Yoo, Sae Hwan Lee, Soung Won Jeong, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Keungmo Yang, Jae Young Jang
  Clinical Nutrition.2025; 47: 119.     CrossRef
• Associations of time in range and glycemic risk index with insulin resistance and diabetic kidney disease in patients with type 2 diabetes
  Zhe Yang, Baozhen Zheng, Guojing Luo, Xiaoyan Xin, Hongyun Lu
  Journal of Diabetes and its Complications.2025; 39(10): 109140.     CrossRef
• Intensive glycemic control and kidney disease risk: insights on hierarchical composite endpoint from a randomized clinical trial
  Zhaojie Song, Haibao Xu, Jiaheng Zhang, Yezhou Liu, Chao Li, Tao Chen, Sujuan Guo, Ni Zhu
  Frontiers in Medicine.2025;[Epub]     CrossRef
• Diagnostic Significance of Elabela, FABP1, and FABP2 as Biomarkers of Diabetic Nephropathy in Type 2 Diabetic Patients
  Samah M. Mohamed, Kholoud S. Ramadan, Ahmed A. Saedii, Ehab A. Ibrahim
  Indian Journal of Clinical Biochemistry.2024;[Epub]     CrossRef